Aspirin Evidence by Cancer Type

This section brings together the aspirin evidence across major cancer types.

The pages do not all say the same thing.

That is the point of the section.

Some cancers have:

• strong prevention signals

• stronger post-diagnosis or anti-metastatic logic

• specific biomarker-defined subgroups

• important negative or mixed findings that change the interpretation

That is why each cancer has its own page.

How to use this section

Use these pages to answer three practical questions:

1. Is there a real human signal in this cancer type?

2. If so, is it prevention, recurrence, survival, or metastasis that looks most relevant?

3. Is the signal broad, or does it depend on dose, duration, subtype, or biomarker status?

Taken together, this section now covers:

• Phase 3 biomarker-selected data in colorectal cancer

• strong prevention signals in liver, pancreatic, and endometrial cancer

• post-surgical recurrence data in prostate cancer

• immunotherapy-combination logic in melanoma

• stem-cell, chemoresistance, and delivery-barrier biology in glioblastoma

• strong metastasis and cisplatin-sensitisation data in osteosarcoma

• a distinct MPN page in myelofibrosis, where aspirin is already clinically relevant for thrombosis but still unproven for disease modification

• a balanced mixed-evidence holding page for additional tumour types

Full cancer pages

• Colorectal Cancer — strongest overall aspirin page, with PIK3CA-selected Phase 3 evidence

• Breast Cancer — mixed but important, including the negative Phase 3 trial and subgroup logic

• Gastric Cancer — strongest in H. pylori-linked, non-cardia, intestinal-type disease

• Liver Cancer (Hepatocellular Carcinoma) — one of the strongest prevention pages, especially in chronic liver disease

• Lung Cancer — long-term prevention plus strong TXA2 and metastasis biology

• Pancreatic Cancer — one of the biggest prevention-effect pages.

• Melanoma — important immunotherapy-combination page with a critical high-dose toxicity lesson

• Glioblastoma — strong preclinical page covering GSCs, TMZ resistance, and the BBB problem

• Osteosarcoma — lung-metastasis suppression and cisplatin sensitisation

• Prostate Cancer — prevention, post-diagnosis survival, post-surgical recurrence, and biomarker-defined subgroups

• Endometrial Cancer — one of the stronger gynaecological aspirin pages, especially in obesity-linked disease

• Ovarian Cancer — real but more modest prevention signal, with histotype-specific differences

• Myelofibrosis — distinct from the solid-tumour pages because aspirin is already used in selected patients for thrombosis, while anti-fibrotic benefit remains unproven

Shorter summaries and mixed-signal areas

• Other Cancer Types — short evidence summaries for bladder cancer, lymphoma subtypes, cervical cancer, and key cautions on cancers that should stay out for now

What this section shows overall

Aspirin is not one simple oncology story.

It looks strongest when one or more of these are true:

• platelet biology and metastatic spread matter

• COX-2 / PGE2 signalling is central to tumour immune evasion

• the cancer develops through a long inflammatory pre-cancer window

• there is a specific molecular subgroup that appears aspirin-sensitive

That is why this section has become one of the most useful ways to judge where aspirin is genuinely promising, where it is still experimental, and where it should be approached with real caution.

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form